Quoin Pharmaceuticals Ltd ADR (QNRX): Next-Year EPS Estimate 50.81%
As of 2026-08-25, Quoin Pharmaceuticals Ltd ADR (QNRX) has a next-year EPS growth estimate of 50.81%. Featured in 4 EPS revision reports, most recently on 2026-07-02.
On 2026-08-21, analyst consensus for QNRX's next-year EPS growth shifted from 53.03% to 50.81% — a negative change of 2.22 percentage points. The revised estimate has been sustained across 4 subsequent trading sessions. Current-year growth is projected at 58.06%.
What's Driving This
The provided EPS data shows a downward revision, not an upgrade: analysts cut next-year growth estimates from 63.86% to 53.03% on 2026-08-17, with the current estimate further slipping to 50.81%. No headline directly ties to an earnings beat or guidance raise; the FDA brand-name approval and Type C meeting updates are plausible catalysts but do not explain an EPS improvement. Thus, the stock's rise is not clearly driven by a positive earnings revision, and any momentum beyond
Generated 2026-08-25 from news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 50.81%
- EPS growth this year
- 58.06%
- EPS next quarter (est)
- -$1.53
- Last price
- $5.07
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 50.81% | 58.06% | -$1.53 | $5.07 |
| 2026-08-24 | 50.81% | 58.06% | -$1.53 | $5.42 |
| 2026-08-23 | 50.81% | 58.06% | -$1.53 | $5.57 |
| 2026-08-21 | 50.81% | 58.06% | -$1.53 | $5.57 |
| 2026-08-20 | 53.03% | 56.08% | -$1.62 | $4.99 |
| 2026-08-19 | 53.03% | 56.08% | -$1.62 | $4.72 |
| 2026-08-18 | 53.03% | 56.08% | -$1.62 | $4.97 |
| 2026-08-17 | 53.03% | 56.08% | -$1.62 | $5.19 |
| 2026-08-16 | 63.86% | 55.97% | -$1.67 | $5.09 |
| 2026-08-14 | 54.80% | 57.09% | -$1.58 | $5.09 |
| 2026-08-13 | 54.84% | 57.06% | -$1.61 | $6.05 |
| 2026-08-12 | 54.84% | 57.06% | -$1.61 | $5.89 |
| 2026-08-11 | 54.84% | 57.06% | -$1.61 | $5.35 |
| 2026-08-10 | 54.84% | 57.06% | -$1.61 | $5.36 |
| 2026-08-09 | 54.84% | 57.06% | -$1.61 | $4.79 |
| 2026-08-07 | 54.84% | 57.06% | -$1.61 | $4.79 |
| 2026-08-06 | 54.84% | 57.06% | -$1.61 | $4.57 |
| 2026-08-05 | 54.84% | 57.06% | -$1.61 | $4.37 |
| 2026-08-04 | 54.84% | 57.06% | -$1.61 | $4.35 |
| 2026-08-03 | 54.84% | 57.06% | -$1.61 | $4.45 |
| 2026-08-02 | 54.84% | 57.06% | -$1.61 | $4.45 |
| 2026-07-31 | 54.84% | 57.06% | -$1.61 | $4.45 |
| 2026-07-30 | 54.84% | 57.06% | -$1.61 | $4.40 |
| 2026-07-29 | 54.84% | 57.06% | -$1.61 | $4.28 |
| 2026-07-28 | 54.84% | 57.06% | -$1.61 | $4.20 |
| 2026-07-27 | 54.84% | 57.06% | -$1.61 | $4.29 |
| 2026-07-26 | 54.84% | 57.06% | -$1.61 | $4.28 |
| 2026-07-24 | 54.84% | 57.06% | -$1.61 | $4.28 |
| 2026-07-23 | 54.84% | 57.06% | -$1.61 | $4.37 |
| 2026-07-22 | 54.84% | 57.06% | -$1.61 | $4.38 |
Reports Featuring QNRX
- 2026-07-02
Top Stock Gainers Driven by EPS Estimate Revisions: QNRX Up 40.9%, IOT Up 24% - July 2, 2026
- 2026-07-01
Top EPS Revision-Driven Movers: QNRX Surges +44.9% as NMAX Sees 376.9% Growth Estimate
- 2026-06-30
QNRX surges 48.9% as EPS revision signal precedes price breakout; HELP, ACMR also climb
- 2026-06-29
EPS Revision Bonanza: LILA +61%, HELP +47%, BDSX +42% Lead Surge
Recent News
- Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI as the Proposed Brand Name for QRX003 for Netherton SyndromeGlobeNewswire
- Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswire
- Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton SyndromeGlobeNewswire
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Quoin Pharmaceuticals Ltd ADR's next-year EPS growth estimate?▾
As of 2026-08-25, Quoin Pharmaceuticals Ltd ADR (QNRX) has a next-year EPS growth estimate of 50.81%, based on analyst consensus.
When was the latest EPS estimate revision for QNRX?▾
The most recent revision occurred on 2026-08-21, when analysts adjusted the next-year EPS growth estimate from 53.03% to 50.81%.
What sector and industry does Quoin Pharmaceuticals Ltd ADR belong to?▾
Quoin Pharmaceuticals Ltd ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. QNRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Quoin Pharmaceuticals Ltd ADR (QNRX) appears here because it was detected by our daily top-EPS-revision-performer screen.